Luminary Therapeutics: Pioneering Advances in CAR-T Therapies with the Allogenic Gamma Delta Platform

Jeff Liter

In a deep-dive conversation with Jeff Liter, CEO of Luminary Therapeutics, we explored the company's unique approach in the fast-evolving landscape of cancer treatment, specifically focusing on Luminary's innovative allogenic Gamma Delta platform and its potential to revolutionize CAR-T therapies and solid tumor trials.

Moe Alsumidaie: Can you delve into Luminary's allogenic Gamma Delta platform and how it reshapes your CAR-T therapies and solid tumor trials?

Jeff Liter: Luminary's allogenic Gamma Delta platform is our 'triple play' strategy, consisting of three key components that each significantly enhance our CAR-T therapies. Firstly, we utilize two subsets of the Gamma Delta cells, Vδ1 and Vδ2, which we believe brings additional potency in fighting cancer cells. Secondly, we incorporate an immune cloaking mechanism that reduces MHC I and MHC II restrictions, hiding the cells from the recipient's immune system and extending their longevity in the patient's body. Finally, we use a nonviral method for cell engineering that reduces costs and accelerates the time to market, giving us a competitive advantage.

MA: How does this platform help optimize production costs and reduce lead times?

JL: Unlike conventional autologous cell therapies, where the manufacturing process requires a clean room environment for a single patient, our allogenic method allows us to distribute the cost over multiple doses from a single manufacturing lot. We anticipate that we should achieve 150 patient doses per manufacturing run. This significant cost reduction facilitates wider accessibility to patients who need these therapies.

MA: Can you share some of your experiences with the operational challenges of implementing CAR-T studies?

JL: Indeed, operational challenges in the CAR-T industry can be pretty significant, especially with autologous therapies. The shift to allogeneic cells will help mitigate these issues, as we can manufacture and freeze down the cells ahead of time, allowing for more streamlined operations.

MA: How does your CAR-T approach navigate this challenge as genetic biomarker-based patient recruitment becomes more prevalent?

JL: Our two Phase I clinical trials do not use specific biomarkers. However, as we gain more insights and understand how the patient population evolves, we anticipate integrating biomarker-based strategies into our patient recruitment process. This will help us to further tailor our therapies to the specific needs of individual patients.

MA: With several biopharmaceutical companies operating in the CAR-T arena, how does Luminary's pipeline differentiate itself?

JL: Our innovative approach focuses on overcoming the critical issue of antigen escape, which is a significant challenge in CAR-T therapies. For blood cancers, we use a single ligand based CAR that can target three antigens at once. We have developed a dual-targeting CAR for solid tumors with a novel and optimized signaling approach that effectively handles tumor microenvironment heterogeneity. These unique attributes enable us to remain competitive in the highly challenging CAR-T space.

MA: Can you expand on your nonviral allogeneic platform and its benefits?

JL: Our nonviral allogeneic platform employs a transposon system, which gives us a considerable advantage in reducing costs and improving time-to-clinic. This nonviral engineering system has facilitated cost savings of around 80%. This factor significantly impacts our cost of goods sold and allows us to deliver cost-effective therapies to more patients.

MA: Can you elaborate on the decision to focus on specific disease indications?

JL: Our strategic focus is to address the issue of antigen escape in various cancers. This focus has led us to design CAR-T therapies that can target a broad spectrum of diseases for instance in our blood program the same CAR is applicable for myeloma, lymphoma, and autoimmune diseases. Our dual targeting CAR for solid tumors will see applicability in recurrent Ovarian, Colorectal and a variety of head and neck cancers. Our single platform approach thus allows us to provide multi-purpose solutions for various cancers.

Moe Alsumidaie, MBA, MSF, is a thought leader and expert in the application of business analytics toward clinical trials, and regular contributor to Applied Clinical Trials.